Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9684656rdf:typepubmed:Citationlld:pubmed
pubmed-article:9684656lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:9684656lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:9684656lifeskim:mentionsumls-concept:C0756081lld:lifeskim
pubmed-article:9684656lifeskim:mentionsumls-concept:C0756085lld:lifeskim
pubmed-article:9684656lifeskim:mentionsumls-concept:C0022877lld:lifeskim
pubmed-article:9684656lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:9684656lifeskim:mentionsumls-concept:C0370215lld:lifeskim
pubmed-article:9684656lifeskim:mentionsumls-concept:C1136254lld:lifeskim
pubmed-article:9684656lifeskim:mentionsumls-concept:C1533691lld:lifeskim
pubmed-article:9684656lifeskim:mentionsumls-concept:C1707454lld:lifeskim
pubmed-article:9684656pubmed:issue5Alld:pubmed
pubmed-article:9684656pubmed:dateCreated1998-8-13lld:pubmed
pubmed-article:9684656pubmed:abstractTextThis report summarizes the activities of quinupristin/dalfopristin (Q/D) and appropriate comparator antibiotics, including ciprofloxacin, erythromycin, gentamicin, rifampin, teicoplanin, and vancomycin, against selected gram-positive pathogens, including Enterococcus faecium, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus agalactiae, and Streptococcus pyogenes. The study pathogens were obtained from 2 sources: (1) clinical isolates taken from patients participating in Q/D worldwide Phase III comparative and noncomparative (emergency-use program) clinical trials; and (2) other isolates collected from the laboratories of 45 geographically distinct medical centers around the world. Q/D was highly active, with minimum inhibitory concentrations (MICs) < or = 1.0 microg/mL against most isolates, including those known to be resistant to methicillin, vancomycin, or erythromycin. Q/D was active (MICs < or = 1 microg/mL) against 95% of the vancomycin-resistant E. faecium strains, for example, whereas ciprofloxacin was active against 6%. Q/D was equally active against methicillin-susceptible or -resistant S. aureus strains (MIC90=1 microg/mL), as was vancomycin (MIC90=2 microg/mL), whereas ciprofloxacin was much less active against methicillin-resistant strains than against methicillin-susceptible strains (MIC90=32 vs 1 microg/mL). Given its spectrum of activity, Q/D may provide a viable option for the treatment of severe respiratory and skin and skin-structure infections caused by gram-positive bacteria, especially when strains with known or suspected resistance to other commonly used antibiotics are present.lld:pubmed
pubmed-article:9684656pubmed:languageenglld:pubmed
pubmed-article:9684656pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9684656pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9684656pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9684656pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9684656pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9684656pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9684656pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9684656pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9684656pubmed:statusMEDLINElld:pubmed
pubmed-article:9684656pubmed:monthMaylld:pubmed
pubmed-article:9684656pubmed:issn0002-9343lld:pubmed
pubmed-article:9684656pubmed:authorpubmed-author:NadlerH LHLlld:pubmed
pubmed-article:9684656pubmed:authorpubmed-author:TalbotGGlld:pubmed
pubmed-article:9684656pubmed:authorpubmed-author:BompartFFlld:pubmed
pubmed-article:9684656pubmed:authorpubmed-author:PeaseMMlld:pubmed
pubmed-article:9684656pubmed:authorpubmed-author:DowzickyMMlld:pubmed
pubmed-article:9684656pubmed:authorpubmed-author:FegerCClld:pubmed
pubmed-article:9684656pubmed:issnTypePrintlld:pubmed
pubmed-article:9684656pubmed:day29lld:pubmed
pubmed-article:9684656pubmed:volume104lld:pubmed
pubmed-article:9684656pubmed:ownerNLMlld:pubmed
pubmed-article:9684656pubmed:authorsCompleteYlld:pubmed
pubmed-article:9684656pubmed:pagination34S-42Slld:pubmed
pubmed-article:9684656pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:meshHeadingpubmed-meshheading:9684656-...lld:pubmed
pubmed-article:9684656pubmed:year1998lld:pubmed
pubmed-article:9684656pubmed:articleTitleEvaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.lld:pubmed
pubmed-article:9684656pubmed:affiliationRhône-Poulenc Rorer Pharmaceuticals, Collegeville, Pennsylvania 19426, USA.lld:pubmed
pubmed-article:9684656pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9684656pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9684656lld:pubmed